相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials
Jonathan G. Pol et al.
ONCOIMMUNOLOGY (2019)
Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
Carmela Passaro et al.
CLINICAL CANCER RESEARCH (2019)
Checkpoint inhibitors go viral
Melanie Senior
NATURE BIOTECHNOLOGY (2019)
Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8(+) T cell responses against HPV16 oncoproteins
Nicolas Cuburu et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System® (RTS®) gene switch as gene therapy for the treatment of glioma
John A. Barrett et al.
CANCER GENE THERAPY (2018)
Armed oncolytic viruses: A kick-start for anti-tumor immunity
J. F. de Graaf et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2018)
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Shetal A. Patel et al.
IMMUNITY (2018)
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma
Frederick F. Lang et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cancer immunotherapy beyond immune checkpoint inhibitors
Julian A. Marin-Acevedo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies
Jacob P. van Vloten et al.
JOURNAL OF IMMUNOLOGY (2018)
Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy
Cheyne Kurokawa et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones
Nikolas Tim Martin et al.
MOLECULAR THERAPY (2018)
Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
Stacy J. Kowalsky et al.
MOLECULAR THERAPY (2018)
Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy
Jacob M. Ricca et al.
MOLECULAR THERAPY (2018)
MicroRNA-Regulated Gene Delivery Systems for Research and Therapeutic Purposes
Bijay Dhungel et al.
MOLECULES (2018)
Durable complete responses in some recurrent highgrade glioma patients treated with Toca 511+Toca FC
Timothy F. Cloughesy et al.
NEURO-ONCOLOGY (2018)
Recurrent Glioblastoma Treated with Recombinant Poliovirus
Annick Desjardins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Dimethyl fumarate potentiates oncolytic virotherapy through NF-kappa B inhibition
Mohammed Selman et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Genomics and emerging biomarkers for immunotherapy of colorectal cancer
Jakob Nikolas Kather et al.
SEMINARS IN CANCER BIOLOGY (2018)
A Recombinant Antibody-Expressing Influenza Virus Delays Tumor Growth in a Mouse Model
Jennifer R. Hamilton et al.
CELL REPORTS (2018)
Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy
Cheyne Kurokawa et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer
Giulia Marelli et al.
FRONTIERS IN IMMUNOLOGY (2018)
Heating it up: Oncolytic viruses make tumors hot' and suitable for checkpoint blockade immunotherapies
Shashi Gujar et al.
ONCOIMMUNOLOGY (2018)
Enhanced Control of Oncolytic Measles Virus Using MicroRNA Target Sites
Mathias Felix Leber et al.
MOLECULAR THERAPY-ONCOLYTICS (2018)
STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer
Abdi Ghaffari et al.
BRITISH JOURNAL OF CANCER (2018)
Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232).
Kevin J. Harrington et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge
Tarsila Mendes de Camargo et al.
SCIENTIFIC REPORTS (2018)
Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment
Amanda Rosewell Shaw et al.
FRONTIERS IN IMMUNOLOGY (2018)
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)
A. Marabelle et al.
ANNALS OF ONCOLOGY (2018)
Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials
Christopher J. LaRocca et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2018)
Integrating oncolytic viruses in combination cancer immunotherapy
Praveen K. Bommareddy et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Current understanding of reovirus oncolysis mechanisms
Matthew B. Phillips et al.
ONCOLYTIC VIROTHERAPY (2018)
Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
Praveen K. Bommareddy et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2017)
Designing and building oncolytic viruses
Justin Maroun et al.
FUTURE VIROLOGY (2017)
Interferon-Mediated Tumor Resistance to Oncolytic Virotherapy
Safieh Ebrahimi et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2017)
The role of stromal cancer-associated fibroblasts in pancreatic cancer
Dagny von Ahrens et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy
Nicholas M. Durham et al.
MOLECULAR THERAPY (2017)
Oncolytic Virotherapy: A Contest between Apples and Oranges
Stephen J. Russell et al.
MOLECULAR THERAPY (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs
Michael C. Brown et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
Dmitriy Zamarin et al.
NATURE COMMUNICATIONS (2017)
Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
Pengju Wang et al.
NATURE COMMUNICATIONS (2017)
Predictors of responses to immune checkpoint blockade in advanced melanoma
N. Jacquelot et al.
NATURE COMMUNICATIONS (2017)
Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
Zuqiang Liu et al.
NATURE COMMUNICATIONS (2017)
How to develop viruses into anticancer weapons
Roberto Cattaneo et al.
PLOS PATHOGENS (2017)
Prospects for combined use of oncolytic viruses and CAR T-cells
Adam Ajina et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
Howard L. Kaufman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection
Rocio Garcia-Carbonero et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Monitoring the efficacy of Oncolytic viruses via Gene expression
Ashley Ansel et al.
FRONTIERS IN ONCOLOGY (2017)
Current immunotherapeutic Strategies to enhance Oncolytic virotherapy
Daniel E. Meyers et al.
FRONTIERS IN ONCOLOGY (2017)
Genetically engineered vaccinia viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery
Dana Haddad
FRONTIERS IN ONCOLOGY (2017)
Immune System, Friend or Foe of Oncolytic Virotherapy?
Anna C. Finley et al.
FRONTIERS IN ONCOLOGY (2017)
Intratumoral immunotherapy: using the tumor as the remedy
A. Marabelle et al.
ANNALS OF ONCOLOGY (2017)
Phase I study of oncolytic virus (OV) MG1 maraba/MAGE-A3 (MG1 MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214.
Derek J. Jonker et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB-IV melanoma.
Jason Alan Chesney et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Mechanisms regulating T-cell infiltration and activity in solid tumors
E. Lanitis et al.
ANNALS OF ONCOLOGY (2017)
Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.
Robert Hans Ingemar Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Local Delivery of OncoVEXmGM-CSF Generates Systemic AntitumorImmuneResponses Enhanced by Cytotoxic T-Lymphocyte-Associated Protein Blockade
Achim K. Moesta et al.
CLINICAL CANCER RESEARCH (2017)
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
Valsamo Anagnostou et al.
CLINICAL CANCER RESEARCH (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models
Jian Zhang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Immune cell profiling in cancer: molecular approaches to cell-specific identification
Yasmin A. Lyons et al.
NPJ PRECISION ONCOLOGY (2017)
Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies
Joshua D. Freedman et al.
EMBO MOLECULAR MEDICINE (2017)
Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade
Dipongkor Saha et al.
CANCER CELL (2017)
Employing RNA viruses to fight cancer: novel insights into oncolytic virotherapy
Doerthe Masemann et al.
BIOLOGICAL CHEMISTRY (2017)
Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination
Hong Jiang et al.
CANCER RESEARCH (2017)
Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy
Mee Y. Bartee et al.
CANCER RESEARCH (2017)
Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses
Yonit Lavin et al.
CELL (2017)
A phase II study of REOLYSINA® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma
Devalingam Mahalingam et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors
Kiyonori Tanoue et al.
CANCER RESEARCH (2017)
Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy
Carlos Alberto Fajardo et al.
CANCER RESEARCH (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis
Monica Khunger et al.
JCO PRECISION ONCOLOGY (2017)
Trial Watch-Oncolytic viruses and cancer therapy
Jonathan Pol et al.
ONCOIMMUNOLOGY (2016)
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
Robert H. I. Andtbacka et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy
Weizhou Hou et al.
CANCER CELL (2016)
Oncolytic virus therapy: A new era of cancer treatment at dawn
Hiroshi Fukuhara et al.
CANCER SCIENCE (2016)
The cGAS-STING Defense Pathway and Its Counteraction by Viruses
Zhe Ma et al.
CELL HOST & MICROBE (2016)
Mechanisms of viral mutation
Rafael Sanjuan et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt et al.
IMMUNITY (2016)
Isolated limb perfusion with biochemotherapy and oncolytic virotherapy combines with radiotherapy and surgery to overcome treatment resistance in an animal model of extremity soft tissue sarcoma
Michelle J. Wilkinson et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
Igor Puzanov et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus
Rachel Myers et al.
MOLECULAR THERAPY (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01
Beatriz Vera et al.
PLOS ONE (2016)
Big Data Offers Novel Insights for Oncolytic Virus Immunotherapy
Stephanie L. Swift et al.
VIRUSES-BASEL (2016)
Oncolytic viruses as immunotherapy: progress and remaining challenges
Laure Aurelian
ONCOTARGETS AND THERAPY (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus
Eric Hastie et al.
ONCOTARGET (2016)
Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis
Tianli Xia et al.
CELL REPORTS (2016)
Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition
Patricia Kleinpeter et al.
ONCOIMMUNOLOGY (2016)
Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice
Eric Bartee et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
Hasan Rehman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study
Howard L. Kaufman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Efficacy analysis of MASTERKEY-265 phase lb study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Recombinant Poxvirus and the Tumor Microenvironment: Oncolysis, Immune Regulation and Immunization
DanielW. Sharp et al.
BIOMEDICINES (2016)
Activity levels of cathepsins B and L in tumor cells are a biomarker for efficacy of reovirus-mediated tumor cell killing
Y. Terasawa et al.
CANCER GENE THERAPY (2015)
Molecular Pathways: Targeting the Stimulator of InterferonGenes(STING) in the Immunotherapyof Cancer
Leticia Corrales et al.
CLINICAL CANCER RESEARCH (2015)
Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy
Kevin J. Harrington et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model
J. Poutou et al.
GENE THERAPY (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Tumor-Infiltrating Dendritic Cells in Cancer Pathogenesis
Jo Marie Tran Janco et al.
JOURNAL OF IMMUNOLOGY (2015)
A Randomized, Controlled Trial of an Aerosolized Vaccine against Measles
N. Low et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Drug-Encoded Biomarkers for Monitoring Biological Therapies
Desislava Tsoneva et al.
PLOS ONE (2015)
Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector
Guido Wollmann et al.
VIROLOGY (2015)
Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?
Samantha Turnbull et al.
VIRUSES-BASEL (2015)
Going viral: a review of replication-selective oncolytic adenoviruses
Christopher Larson et al.
ONCOTARGET (2015)
Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
Ilkka Liikanen et al.
ONCOIMMUNOLOGY (2015)
OX40 agonists anc combination immunotherapy: putting the pedal to the metal
Stefanie N. Linch et al.
FRONTIERS IN ONCOLOGY (2015)
Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer
Evanthia Galanis et al.
CANCER RESEARCH (2015)
Aerosol gene delivery using viral vectors and cationic carriers for in vivo lung cancer therapy
Seong-Ho Hong et al.
EXPERT OPINION ON DRUG DELIVERY (2015)
Isolated limb perfusion with melphalan, tumour necrosis factor-alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma
Tim D. Pencavel et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Molecular imaging of oncolytic viral therapy
Dana Haddad et al.
MOLECULAR THERAPY-ONCOLYTICS (2015)
Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor-Modified T Cells in Solid Tumors
Nobuhiro Nishio et al.
CANCER RESEARCH (2014)
Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF
Weizhou Hou et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Combined Adenovirus Vector and Hepatitis C Virus Envelope Protein Prime-Boost Regimen Elicits T Cell and Neutralizing Antibody Immune Responses
Alicja M. Chmielewska et al.
JOURNAL OF VIROLOGY (2014)
CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
Christine E. Engeland et al.
MOLECULAR THERAPY (2014)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Dmitriy Zamarin et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Safety and immunogenicity of dry powder measles vaccine administered by inhalation: A randomized controlled Phase I clinical trial
Sharad Agarkhedkar et al.
VACCINE (2014)
Oncolytic Viruses and Their Application to Cancer Immunotherapy
E. Antonio Chiocca et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses
Andrew Zloza et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Convection-enhanced delivery improves distribution and efficacy of tumor-selective retroviral replicating vectors in a rodent brain tumor model
D. Yin et al.
CANCER GENE THERAPY (2013)
Enhanced Tumor Uptake and Penetration of Virotherapy Using Polymer Stealthing and Focused Ultrasound
Robert Carlisle et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Jeong Heo et al.
NATURE MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Update on oncolytic viral therapy - targeting angiogenesis
James R. Tysome et al.
ONCOTARGETS AND THERAPY (2013)
Pre-existing Anti-Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy
Vedell Louis Jeune et al.
HUMAN GENE THERAPY METHODS (2013)
Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+ T-cell responses to anticancer vaccines
Byram W. Bridle et al.
ONCOIMMUNOLOGY (2013)
Oncolytic Herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation
S. Yamada et al.
CANCER GENE THERAPY (2012)
A novel conditionally replicating adenoviral vector with dual expression of IL-24 and arresten inserted in E1 and the region between E4 and fiber for improved melanoma therapy
L. Chai et al.
CANCER GENE THERAPY (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Expression of CCL19 from Oncolytic Vaccinia Enhances Immunotherapeutic Potential while Maintaining Oncolytic Activity
Jun Li et al.
NEOPLASIA (2012)
Systemic Delivery of Oncolytic Viruses: Hopes and Hurdles
Mark S. Ferguson et al.
ADVANCES IN VIROLOGY (2012)
Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT
J. C. Doloff et al.
CANCER GENE THERAPY (2011)
Activating Systemic T-Cell Immunity Against Self Tumor Antigens to Support Oncolytic Virotherapy with Vesicular Stomatitis Virus
Phonphimon Wongthida et al.
HUMAN GENE THERAPY (2011)
Myeloma Xenograft Destruction by a Nonviral Vector Delivering Oncolytic Infectious Nucleic Acid
Elizabeth M. Hadac et al.
MOLECULAR THERAPY (2011)
Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide
Alan Melcher et al.
MOLECULAR THERAPY (2011)
MicroRNA-sensitive Oncolytic Measles Viruses for Cancer-specific Vector Tropism
Mathias F. Leber et al.
MOLECULAR THERAPY (2011)
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
Caroline J. Breitbach et al.
NATURE (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Induction of type I interferon by RNA viruses: cellular receptors and their substrates
Alina Baum et al.
AMINO ACIDS (2010)
Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck
Kevin J. Harrington et al.
CLINICAL CANCER RESEARCH (2010)
Impact of tumor microenvironment on oncolytic viral therapy
Jeffrey Wojton et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2010)
Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy
I-K Choi et al.
GENE THERAPY (2010)
Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?
T. Pencavel et al.
GENE THERAPY (2010)
Phase I/II Study of Oncolytic Herpes Simplex Virus NV1020 in Patients with Extensively Pretreated Refractory Colorectal Cancer Metastatic to the Liver
Sunil K. Geevarghese et al.
HUMAN GENE THERAPY (2010)
Synergistic Interaction Between Oncolytic Viruses Augments Tumor Killing
Fabrice Le Boeuf et al.
MOLECULAR THERAPY (2010)
Enhancing the Therapeutic Effect Against Ovarian Cancer Through a Combination of Viral Oncolysis and Antigen-specific Immunotherapy
Yu-Qian Zhang et al.
MOLECULAR THERAPY (2010)
Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice
Y. Kulu et al.
CANCER GENE THERAPY (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
The significance of OX40 and OX40L to T-cell biology and immune disease
Michael Croft et al.
IMMUNOLOGICAL REVIEWS (2009)
Hypercostimulation through 4-1BB Distorts Homeostasis of Immune Cells
Seung-Woo Lee et al.
JOURNAL OF IMMUNOLOGY (2009)
E4orf1 Limits the Oncolytic Potential of the E1B-55K Deletion Mutant Adenovirus
Michael A. Thomas et al.
JOURNAL OF VIROLOGY (2009)
Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity
Robin J. Prestwich et al.
CLINICAL CANCER RESEARCH (2008)
Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models
Shanthi Ganesh et al.
CLINICAL CANCER RESEARCH (2008)
Factors influencing retention of adenovirus within tumours following direct intratumoural injection
M. Bazan-Peregrino et al.
GENE THERAPY (2008)
Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial
C. L. White et al.
GENE THERAPY (2008)
Generation of a Conditionally Replicating Adenovirus Based on Targeted Destruction of E1A mRNA by a Cell Type-Specific MicroRNA
Erkko Ylosmaki et al.
JOURNAL OF VIROLOGY (2008)
Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide
Mark A. Currier et al.
MOLECULAR THERAPY (2008)
Recombinant Newcastle Disease Virus as a Vaccine Vector for Cancer Therapy
Adam Vigil et al.
MOLECULAR THERAPY (2008)
A let-7 microRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication
Robert E. Edge et al.
MOLECULAR THERAPY (2008)
Role for herpes simplex virus 1 ICP27 in the inhibition of type I interferon signaling
Karen E. Johnson et al.
VIROLOGY (2008)
Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene
S. Chalikonda et al.
CANCER GENE THERAPY (2008)
Herpes simplex virus type 1 preferentially targets human colon carcinoma: Role of extracellular matrix
Dror Kolodkin-Gal et al.
JOURNAL OF VIROLOGY (2008)
CD8 T cell dysfunction during chronic viral infection
Haina Shin et al.
CURRENT OPINION IN IMMUNOLOGY (2007)
Cytokine-independent upregulation of MDA5 in viral infection
Jacob S. Yount et al.
JOURNAL OF VIROLOGY (2007)
Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor
Tanja I. Naslund et al.
JOURNAL OF IMMUNOLOGY (2007)
Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways
Jiangao Zhu et al.
JOURNAL OF VIROLOGY (2007)
An optimized clinical regimen for the oncolytic virus PV701
Sebastien J. Hotte et al.
CLINICAL CANCER RESEARCH (2007)
Systemic efficacy with oncolytic virus therapeutics: Clinical proof-of-concept and future directions
Ta-Chiang Liu et al.
CANCER RESEARCH (2007)
Herpes simplex virus 1 (HSV-1) for cancer treatment
Y. Shen et al.
CANCER GENE THERAPY (2006)
Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy
Joo-Hang Kim et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412
Ganesh Suntharalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model
K. -W. Peng et al.
CANCER GENE THERAPY (2006)
Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect
K-J Choi et al.
GENE THERAPY (2006)
Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control
Guy R. Simpson et al.
CANCER RESEARCH (2006)
A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization
SA Laurie et al.
CLINICAL CANCER RESEARCH (2006)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer
F Benencia et al.
MOLECULAR THERAPY (2005)
The HSV-1 Us3 protein kinase is sufficient to block apoptosis induced by overexpression of a variety of Bcl-2 family members
PD Ogg et al.
VIROLOGY (2004)
Overexpression of adenovirus E3-11.6K protein induces cell killing by both caspase-dependent and caspase-independent mechanisms
AH Zou et al.
VIROLOGY (2004)
Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway
J Fueyo et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
BL Liu et al.
GENE THERAPY (2003)
Alpha/beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1
B Sainz et al.
JOURNAL OF VIROLOGY (2002)
ICOS co-stimulatory receptor is essential for T-cell activation and function
C Dong et al.
NATURE (2001)
Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor
M Toda et al.
MOLECULAR THERAPY (2000)
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
DF Stojdl et al.
NATURE MEDICINE (2000)
Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer
T Hermiston
JOURNAL OF CLINICAL INVESTIGATION (2000)
分享论文
